Spanish, Italian, and French health authorities expand recommendations for use of Novavax COVID-19 vaccine.
The WHO updates its recommendations for the use of COVID-19 therapeutics, considering new evidence of the reduction of effectiveness against circulating Omicron variants.
Shionogi announces the initiation of a Phase1/2/3 clinical trial in Japanese pediatric subjects for the COVID-19 recombinant protein-based vaccine, S-268019.
An independent report commissioned by IFPMA points to an increased politicization of access to samples and sequence information on pathogens, finding serious shortcomings, including the fact that the international framework on accessing and sharing pathogens is putting severe strain on the global health community's ability to control future outbreaks.
The European Medicines Agency (EMA) recommends to convert Pfizer's COVID-19 antiviral, Paxlovid, from conditional market authorization to full market authorization.
The International Pandemic Preparedness Secretariat (IPPS) publishes the Second Implementation Report of the 100 Days Mission, identifying six focus areas for international effort and support in 2023. The report underlines the importance of access to pathogens and underscores the value of the Berlin Declaration proposal to ensure equitable access to countermeasures.
Shionogi advances Ensitrelvir Fumaric Acid COVID-19 antiviral clinical program.
Gilead Sciences announces that three different real world studies confirm the ability of its COVID-19 antiviral, remdesivir, to reduce risk of mortality in hospitalized patients.
Pfizer and BioNTech submit supplemental biologics license application for US FDA approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for ages 12 years and older as primary series or booster.